Olema Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
OLMA$7.36+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(Amounts in thousands, except for share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $68,539 | $23,702 |
| Marketable securities | 193,268 | 180,719 |
| Prepaid expenses and other current assets | 4,706 | 4,478 |
| Total current assets | 266,513 | 208,899 |
| Operating lease right-of-use assets | 2,291 | 2,495 |
| Other assets and long-term deposits | 8,141 | 4,251 |
| Total assets | $276,945 | $215,645 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $2,698 | $374 |
| Operating lease liabilities, current | 988 | 1,015 |
| Other current liabilities | 17,935 | 15,160 |
| Total current liabilities | 21,621 | 16,549 |
| Operating lease liabilities, net of current portion | 1,429 | 1,550 |
| Total liabilities | 23,050 | 18,099 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022. | — | — |
| Common stock, $0.0001 par value; 490,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 55,097,118 and 40,601,648 shares issued as of December 31, 2023 and December 31, 2022, respectively; 54,992,784 and 40,287,097 shares outstanding as of December 31, 2023 and December 31, 2022, respectively. | 4 | 3 |
| Additional paid-in capital | 559,176 | 408,333 |
| Accumulated other comprehensive gain (loss) | 347 | (1,813) |
| Accumulated deficit | (305,632) | (208,977) |
| Total stockholders’ equity | 253,895 | 197,546 |
| Total liabilities and stockholders’ equity | $276,945 | $215,645 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.